Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates AHCJ's social media efforts and edits and manages production of association guides, programs and newsletters.
The Association of Health Care Journalists has awarded AHCJ Reporting Fellowships on Health Care Performance to five journalists who intend to pursue significant projects in 2021. The program, in its 11th year, is meant to help journalists understand and report on the performance of local health care markets and the U.S. health system as a whole.
The fellowship program, supported by The Commonwealth Fund, is intended to give experienced print, broadcast and online reporters an opportunity to concentrate on the performance of health care systems – or significant parts of those systems – locally, regionally or nationally. The fellows are able to examine policies, practices and outcomes, as well as the roles of various stakeholders.
Journalists interested in building careers reporting on science, health and the environment are eligible to apply for new cross-cutting fellowships designed to provide training, networking, mentoring, new sources and story ideas, while allowing them to stay at their jobs.
The National Science-Health-Environment Reporting Fellowships are a first-ever collaboration of the Council for the Advancement of Science Writing (CASW), the Association of Health Care Journalists (AHCJ), and the Society of Environmental Journalists (SEJ). The year-long fellowships are open to early-career journalists interested in covering any or all of the three fields.
While describing the efforts of the National Institutes of Health and its partnerships with other agencies and pharmaceutical companies, NIH Director Francis Collins described the endeavor as “the most amazing outpouring of scientific capabilities, determination, talent that I’ve ever seen in my 27 years at NIH.”
During a recorded keynote speech at AHCJ’s Journalism Summit on Infectious Disease on Nov. 18, Collins said “The news [about recently announced vaccine trials] is extremely good. Both of these involving trials of 30,000 or more participants have been able to show that the messenger RNA-based vaccine strategy has resulted in over 90% efficacy for both of these and what appears to be a very reasonable safety record as well.” Continue reading →